Dr. Richard Koya, M.D., PhD. serve as the Chief Scientific Officer for Tactiva Therapeutics. He is also the Director of the Vector Development and Production Facility and the Associate Director of the Center for Immunotherapy at Roswell Park Cancer Institute (RPCI); Associate Professor of Oncology and member of the Tumor Immunology and Immunotherapy CCSG Program at RPCI. Dr. Koya was previously an assistant professor in the Department of Surgery, Division of Surgical Oncology, UCLA, with research focus in cancer gene therapy and immunology. Dr. Koya maintains an active research program focused on finding new and efficacious therapies for cancer based on immunotherapy and gene therapy. Dr. Koya is an author of many high-impact publications in the field of cancer research, and he currently leads a National Institutes of Health (NIH) prospective clinical trials program based on immune modulator/enhancer, T Cell Receptor-engineered T cell transfer for metastatic cancer patients. He also serves as a peer reviewer for various scientific journals in the field of cancer research and immunology and as reviewer for grants in scientific review study sections of the NIH and National Cancer Institute (NCI). Dr. Koya has received many awards; among them are the Scholar Award from the Ministry of Education and Culture of Japan, the Ito Foundation Award, the Nickel-V Foundation Award, and the STOP CANCER Award.